openPR Logo
Press release

Clinical Trials & Results of Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics |Top Key Players are AVEO Oncology, Galaxy Biotech, LLC, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd.,

06-12-2019 11:38 AM CET | Health & Medicine

Press release from: Pharma Proff

Clinical Trials & Results of Hepatocyte Growth Factor (HGF)

Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis.

Download the sample report @ https://www.pharmaproff.com/request-sample/1201

Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed as a monotherapy or as combination therapy with RAS-RAF-MEK, AKT-mTOR, and EGFR inhibitors for the treatment of various human cancers. HGF inhibitors have shown potent antineoplastic effects in several clinical trials for the treatment of head and neck squamous cell carcinoma as HGF/c-Met pathway is directly involved in the development of a proliferative, invasive, and metastatic cancer.

Get the detailed analysis @ https://www.pharmaproff.com/report/hepatocyte-growth-factor-inhibitor

AVEO Pharmaceuticals Inc. is in the process of developing Ficlatuzumab as a potent HGF inhibitor antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities for the treatment of squamous cell carcinoma of the head and neck and acute myeloid leukemia. Galaxy Biotech LLC, Daiichi Sankyo Company Limited, and Taiho Pharmaceutical Co. are some other companies having HGF inhibitor pipeline.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1201

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clinical Trials & Results of Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics |Top Key Players are AVEO Oncology, Galaxy Biotech, LLC, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., here

News-ID: 1772646 • Views: 631

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for HGF

Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019 | …
Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis. Download the sample report @ https://www.pharmaproff.com/request-sample/1201 Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed
c-MET/HGF Inhibitors Market Production and CAGR (%) Comparison by Types
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
C-MET / HGF Inhibitors Global Market 2019 Top Key Players – Abxign,  Abbott L …
Global C-MET / HGF Inhibitors Market WiseGuyRerports.com Presents Global C-MET / HGF Inhibitors Market Insights, Forecast to 2025” New Document to its Studies Database. The Report Contain 148 Pages With Detailed Analysis. Description c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during
c-MET / HGF Inhibitors Market to Record an Exponential CAGR by 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
C Met Hgf Inhibitors Market Set to Witness an Uptick During 2017 - 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
c-MET / HGF Inhibitors Market to Register Steady Growth During 2017- 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several